Prognosis of non-small cell lung cancer with postoperative regional lymph node recurrence
© 2024 The Authors. Thoracic Cancer published by John Wiley & Sons Australia, Ltd..
BACKGROUND: Regional lymph node recurrence after radical surgery for non-small cell lung cancer (NSCLC) is an oligo-recurrent disease; however, no treatment strategy has been established. In the present study we aimed to determine the clinical outcomes of postoperative regional lymph node recurrence and identify prognostic predictors in the era of molecular-targeted therapy.
METHODS: We retrospectively analyzed data on clinical characteristics and outcomes of patients with regional lymph node recurrence after surgery who underwent treatment for NSCLC between 2002 and 2022.
RESULTS: A total of 53 patients were included in this study. The median time between surgery and detection of recurrence was 1.21 years. Radiotherapy (RT) alone and chemoradiotherapy (CRT) were performed in 38 and six patients, respectively. Driver gene alterations were detected in eight patients (EGFR: 6, ROS1:1, and BRAF: 1) and programmed death-ligand 1 (PD-L1) expression was examined in 22 patients after 2016. Median progression-free survival (PFS) and overall survival (OS) after lymph node recurrences were 1.32 and 4.34 years, respectively. Multiple lymph node recurrence was an independent prognostic factor for PFS, whereas driver gene alteration was the only prognostic factor for OS. There was no significant difference in the OS between patients stratified according to the initial treatment modality for lymph node recurrence.
CONCLUSION: Our results suggest that the number of tumor recurrences may correlate with PFS, while detection of driver gene alterations could guide decision-making for the appropriate molecular-targeted therapy to achieve longer OS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Thoracic cancer - 15(2024), 11 vom: 28. Apr., Seite 859-866 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ohtaki, Yoichi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chemoradiotherapy |
|---|
| Anmerkungen: |
Date Completed 16.04.2024 Date Revised 17.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/1759-7714.15265 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369042417 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369042417 | ||
| 003 | DE-627 | ||
| 005 | 20240417232540.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/1759-7714.15265 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1378.xml |
| 035 | |a (DE-627)NLM369042417 | ||
| 035 | |a (NLM)38414316 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ohtaki, Yoichi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognosis of non-small cell lung cancer with postoperative regional lymph node recurrence |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.04.2024 | ||
| 500 | |a Date Revised 17.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Thoracic Cancer published by John Wiley & Sons Australia, Ltd. | ||
| 520 | |a BACKGROUND: Regional lymph node recurrence after radical surgery for non-small cell lung cancer (NSCLC) is an oligo-recurrent disease; however, no treatment strategy has been established. In the present study we aimed to determine the clinical outcomes of postoperative regional lymph node recurrence and identify prognostic predictors in the era of molecular-targeted therapy | ||
| 520 | |a METHODS: We retrospectively analyzed data on clinical characteristics and outcomes of patients with regional lymph node recurrence after surgery who underwent treatment for NSCLC between 2002 and 2022 | ||
| 520 | |a RESULTS: A total of 53 patients were included in this study. The median time between surgery and detection of recurrence was 1.21 years. Radiotherapy (RT) alone and chemoradiotherapy (CRT) were performed in 38 and six patients, respectively. Driver gene alterations were detected in eight patients (EGFR: 6, ROS1:1, and BRAF: 1) and programmed death-ligand 1 (PD-L1) expression was examined in 22 patients after 2016. Median progression-free survival (PFS) and overall survival (OS) after lymph node recurrences were 1.32 and 4.34 years, respectively. Multiple lymph node recurrence was an independent prognostic factor for PFS, whereas driver gene alteration was the only prognostic factor for OS. There was no significant difference in the OS between patients stratified according to the initial treatment modality for lymph node recurrence | ||
| 520 | |a CONCLUSION: Our results suggest that the number of tumor recurrences may correlate with PFS, while detection of driver gene alterations could guide decision-making for the appropriate molecular-targeted therapy to achieve longer OS | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a chemoradiotherapy | |
| 650 | 4 | |a driver gene | |
| 650 | 4 | |a lymph node recurrence | |
| 650 | 4 | |a non‐small cell lung cancer (NSCLC) | |
| 650 | 4 | |a radiotherapy | |
| 650 | 7 | |a Protein-Tyrosine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins |2 NLM | |
| 700 | 1 | |a Nagashima, Toshiteru |e verfasserin |4 aut | |
| 700 | 1 | |a Okano, Naoko |e verfasserin |4 aut | |
| 700 | 1 | |a Kubo, Nobuteru |e verfasserin |4 aut | |
| 700 | 1 | |a Ohtaka, Takeru |e verfasserin |4 aut | |
| 700 | 1 | |a Sunaga, Noriaki |e verfasserin |4 aut | |
| 700 | 1 | |a Sakurai, Reiko |e verfasserin |4 aut | |
| 700 | 1 | |a Miura, Yosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Nakazawa, Seshiru |e verfasserin |4 aut | |
| 700 | 1 | |a Kawatani, Natsuko |e verfasserin |4 aut | |
| 700 | 1 | |a Yazawa, Tomohiro |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshikawa, Ryohei |e verfasserin |4 aut | |
| 700 | 1 | |a Narusawa, Eiji |e verfasserin |4 aut | |
| 700 | 1 | |a Shirabe, Ken |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Thoracic cancer |d 2010 |g 15(2024), 11 vom: 28. Apr., Seite 859-866 |w (DE-627)NLM251832414 |x 1759-7714 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:11 |g day:28 |g month:04 |g pages:859-866 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/1759-7714.15265 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 11 |b 28 |c 04 |h 859-866 | ||